---
title: "BUZZ-United Therapeutics gains after $2 bln buyback announced"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278432902.md"
datetime: "2026-03-09T18:25:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278432902.md)
  - [en](https://longbridge.com/en/news/278432902.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278432902.md)
---

# BUZZ-United Therapeutics gains after $2 bln buyback announced

United Therapeutics (UTHR.O) shares up 7.6% to $514.45 on Mon after announcing new $2 bln stock buyback Silver Spring, Maryland-based firm early Mon said board-authorized repurchase program includes initial $1.5 bln ASP (accelerated share repurchase) agreements with Citibank (C.N)

Remaining amount of up to $500 mln will be available for additional buybacks at co’s discretion Buyback announcement comes one week after co said its drug, ralinepag, to treat a rare lung condition cut the risk of the disease worsening in late-stage study

UTHR markets other FDA-approved pulmonary arterial hypertension (PAH) treatments, including oral drug Orenitram, continuous infusion therapy, Remodulin and inhaler-based Tyvaso and Tyvaso DPI

TD Cowen, which rates UTHR ‘buy’ with $575 PT, says in note it believes the timing of the ASR program signals management’s confidence in executing across the commercial franchise

UTHR has nearly $23 bln market cap, based on ~43.8 mln shares outstanding

With move on the session, stock up 6% YTD vs ~4% drop in Nasdaq (.IXIC) . Shares are off ~4% from Feb 25 record intraday high of $537.19

Avg rating of 15 brokerages is “buy”; median PT of $575 up from $525 a month ago, per LSEG data (Lance Tupper is a Reuters market analyst. The views expressed are his own)

### Related Stocks

- [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md)

## Related News & Research

- [How FDA RMAT Status For Bioengineered Liver Device At United Therapeutics (UTHR) Has Changed Its Investment Story](https://longbridge.com/en/news/282975066.md)
- [United Therapeutics Director Sold Shares Worth Over $1.0M](https://longbridge.com/en/news/280686000.md)
- [These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings](https://longbridge.com/en/news/277085456.md)
- [United Therapeutics' lung disease drug succeeds in late-stage study](https://longbridge.com/en/news/277457826.md)
- [United Therapeutics Corporation Files Initial Statement of Beneficial Ownership for Director Kevin Tracey](https://longbridge.com/en/news/273557357.md)